In the last trading session, 3.43 million shares of the KalVista Pharmaceuticals Inc (NASDAQ:KALV) were traded, and its beta was 0.01. Most recently the company’s share price was $14.95, and it changed around -$0.11 or -0.73% from the last close, which brings the market valuation of the company to $743.25M. KALV currently trades at a discount to its 52-week high of $15.91, offering almost -6.42% off that amount. The share price’s 52-week low was $7.30, which indicates that the current value has risen by an impressive 51.17% since then. We note from KalVista Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 2.52 million shares, with the 3-month average coming to 913.80K.
KalVista Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended KALV as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
Instantly KALV has showed a red trend with a performance of -0.73% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 16.14 on recent trading dayincreased the stock’s daily price by 7.37%. The company’s shares are currently up 27.56% year-to-date, but still up 32.24% over the last five days. On the other hand, KalVista Pharmaceuticals Inc (NASDAQ:KALV) is 8.33% up in the 30-day period. We can see from the shorts that 6.25 million shares have been sold at a short interest cover period of 11.1 day(s).
The consensus price target as assigned by Wall Street analysts is $20, which translates to bulls needing to increase their stock price by 25.25% from its current value. Analyst projections state that KALV is forecast to be at a low of $20 and a high of $28.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.06%. KalVista Pharmaceuticals Inc earnings are expected to increase by -3.66% in 2025, but the outlook is positive 30.75% per year for the next five years.
KALV Dividends
KalVista Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Mar-12.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.47% of KalVista Pharmaceuticals Inc shares, and 112.39% of them are in the hands of institutional investors. The stock currently has a share float of 114.06%. KalVista Pharmaceuticals Inc stock is held by 174.0 institutions, with VR ADVISER, LLC being the largest institutional investor. By 2024-06-30, it held 13.5179% of the shares, which is about 6.25 million shares worth $73.62 million.
TANG CAPITAL MANAGEMENT LLC, with 9.1252% or 4.22 million shares worth $49.7 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 3.18 shares worth $47.5 million, making up 6.39% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 1.4 shares worth around $20.91 million, which represents about 2.81% of the total shares outstanding.
